European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-27

Genome Maintenance in the Context of Chromatin

Objetivo

With the availability of the essentially complete sequence of the human genome, as well as a rapid development of massive sequencing techniques, the research efforts to understand genetics and disease from a cis standpoint will soon reach an endpoint. However, our emerging knowledge of gene regulation networks reveals that epigenetic regulation of the hereditary information plays crucial roles in various biological events through its influence on processes such as transcription, DNA replication and chromosome architecture. Another scenario in which the control of chromatin structure is crucial is the repair of lesions in genomic DNA. There is mounting evidence, particularly from model organisms such as Saccharomyces cerevisiae, that histone modifying enzymes (acetylases, deacetylases, kinases, …) are essential components of the machinery that maintains genome integrity and thereby guards against cancer, degenerative diseases and ageing. However, little is known about the specific “code” of histone tail modifications that coordinate DNA repair, and the impact that an aberrant “histone code” may have on human health. In CHROMOREPAIR we will systematically analyze the chromatin remodelling process that undergoes at DNA lesions and evaluate the impact that chromatin alterations have on the access, signaling and repair of DNA damage. Furthermore, we propose to translate our in vitro knowledge to the development of mouse models that help us evaluate how modulation of chromatin status impinges on genome maintenance and therefore on cancer and aging. As a provocative line of research and based on our preliminary data, we propose that certain chromatin alterations could not only impair but also in some cases promote a more robust response to DNA breaks, which could be a novel and not yet explored way to potentiate the elimination of pre-cancerous cells.

Convocatoria de propuestas

ERC-2007-StG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-SG - ERC Starting Grant

Institución de acogida

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Aportación de la UE
€ 948 426,00
Dirección
C MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
España

Ver en el mapa

Región
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo de actividad
Research Organisations
Contacto administrativo
Dolores Liebanes (Dr.)
Investigador principal
Oscar Fernández-Capetillo Ruiz (Dr.)
Enlaces
Coste total
Sin datos

Beneficiarios (1)